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Abstract 
The effect of pretreatment with pertussis toxin at the doses of 0.25 and 0.50 Ixg per mouse i.c.v, on the analgesic effect produced by 
morphine (7 mg kg-l s.c.), baclofen (4 mg kg -t s.c.), diphenhydramine (20 mg kg-1 s.c.), clomipramine (25 mg kg I s.c.) and 
physostigmine (0.1-0.2 mg kg- t s.c.) was investigated in the mouse hot-plate test. Seven days after a single injection of pertussis toxin, 
inhibition of morphine and diphenhydramine analgesia was observed, whereas 11 days after pertussis toxin pretreatment, baclofen- and 
clomipramine-induced antinociception was also reduced. By contrast, pertussis toxin had no effect on physostigmine-induced antinocicep- 
tion. The present results indicate that the activation of pertussis toxin-sensitive G-proteins represents an important transduction step in the 
central analgesia induced by opioids, antihistaminics, GABA B (',/-aminobutyric a id B) agonists and tricyclic antidepressants, butnot by 
cholinomimetics. 
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1. Introduction 
Numerous neurotransmitters, such as opioids, acetyl- 
choline, GABA (~-aminobutyric acid), cathecolamines, 
serotonin, purines, histamine, somatostatin, europeptide 
Y, calcitonin, are involved in pain inhibition. All these 
molecules have been demonstrated to interact with 
metabotropic receptors coupled to G-proteins (Graziano 
and Gilman, 1987; Birnbaumer, 1990), leading to the 
modulation of intracellular effectors including adenylate 
cyclase, phospholipase C ~Lnd ion channels (Bourne et al., 
1990, 1991; Simon et al., 1991). G-proteins are het- 
erotrimeric molecules with or, 13 and ~/ subunits. The et 
subunits can be classified into families, depending on 
whether they are targets far cholera toxin (Gs), pertussis 
toxin (G i and G o) or neither (Gq and Gl2) (Simon et al., 
1991; Hepler and Gilman, 1992). Pertussis toxin-sensitive 
G-proteins represent the most widespread modulatory sig- 
naling pathway in neurones (Holz et al., 1986) and are 
responsible for inhibition of adenylate cyclase activity and 
modulation of several K + and Ca 2+ channels (Brown and 
Birnbaumer, 1990; Hepler and Gilman, 1992; Hille, 1994). 
* Corresponding author. Tel.: + 39 55 4237432; fax: + 39 55 4361613. 
Activation of opioid and et 2-adrenoceptors causes inhi- 
bition of adenylate cyclase activity and regulates ionic 
conductance, as documented by biochemical and electro- 
physiological studies (Sharma et al., 1975; Sabol and 
Nirenberg, 1979; Brown and Birnbaumer, 1990), via per- 
tussis toxin-sensitive G-proteins (Childers, 1991; Aghaja- 
nian and Wang, 1986, Dunwiddie and Su, 1988). Simi- 
larly, the stimulation of GABA B and adenosine A~ recep- 
tors provokes inhibition of adenylate cyclase in rat brain 
slices (Hill, 1985) and in cultured brain cells (Van Calker 
et al., 1979), the opening of several K + channels in central 
neurones (GS.hwiler and Brown, 1985; Trussel and Jack- 
son, 1987) and a reduction of Ca 2+ currents in dorsal root 
ganglion cells (Dolphin and Scott, 1987; McDonald et al., 
1986) by a pertussis toxin-inhibitable mechanism. 
With regard to in vivo studies, it has been reported that 
injection of pertussis toxin in mice and rats blocks both 
spinal and supraspinal morphine-, noradrenaline- and 
clonidine-induced antinociception (Parenti et al., 1986; 
Hoehn et al., 1988; Sanchez-Blazquez and Garzon, 1991) 
regardless of the route of administration or the analgesic 
test used (Parolaro et al., 1990). Furthermore, intrathecally 
administered pertussis toxin has been shown to be able to 
prevent antinociception i duced by intrathecal injection of 
baclofen (Hoehn et al., 1988) and purines (Sawynok and 
Reid, 1988) in rats. 
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Since it has been demonstrated that opioid, a-adren- 
ergic, GABAergic and purinergic analgesic effects are 
mediated by pertussis toxin-sensitive G-proteins, we 
thought it worthwhile to extend the investigation to the 
biochemical mechanisms of other pain inhibitory systems 
to provide some indication of whether a Gi/o protein is 
involved in central antinociception. To this end, drugs 
modulating cholinergic, serotoninergic and histaminergic 
systems were investigated since they not only represent 
central analgesic compounds effective in both animals 
(Harris et al., 1969; Sacerdote t al., 1978; Rumore and 
Schlichting, 1985) and humans (Hood et al., 1995; Lang- 
ohr et al., 1982; Campos and Solis, 1980), but also they 
interact with G-protein-coupled receptors (Birnbaumer, 
1990). The effect of intracerebroventricular injection of 
pertussis toxin on the antinociception i duced by adminis- 
tration of the t~-~ opioid receptor agonist morphine, the 
GABA B agonist baclofen, the tricyclic antidepressant 
clomipramine, the cholinesterase inhibitor physostigmine 
and the histamine H~ receptor antagonist diphenhydramine 
was, therefore, evaluated in mice. 
2. Materials and methods 
2.1. Animals 
Male Swiss albino mice (23-30 g) were used. Fifteen 
mice were housed per cage. The cages were placed in the 
experimental room 24 h before the test for acclimatization. 
The animals were fed on a standard laboratory diet and tap 
water ad libitum. Mice were randomly assigned to a 
vehicle (water solution containing 0.01 M sodium phos- 
phate buffer, pH 7.0, with 0.05 sodium chloride) or a 
pertussis toxin group (0.25 and 0.50 p~g per mouse). Naive 
animals did not receive any pretreatment whereas vehicle 
and pertussis toxin groups received a single intracere- 
broventricular injection on day 0. 
2.2. Hot-plate test 
Mice were placed inside a stainless steel container, 
thermostatically set at 52.5 _+ 0.1°C in a precision water- 
bath from CW Mechanical Workshop, Siena, Italy. Reac- 
tion times (s) were measured with a stopwatch and each 
animal was tested before and 15, 30, 45 and 60 min after 
treatment. The endpoint used was the licking of the fore or 
hind paws. Those mice scoring below 12 and over 18 s in 
the pretest were rejected. An arbitrary cut-off time of 45 s 
was adopted. Following a single pretreatment with vehicle 
or pertussis toxin, the antinociceptive effect of morphine 
and diphenhydramine was tested 2 and 7 days later, the 
antinociceptive effect of baclofen and clomipramine 2, 7 
and 11 days later and the antinociceptive ffect of 
physostigmine 2, 7, 11 and 14 days later. 
2.3. Rota-rod test 
The apparatus consisted of a base platform and a rotat- 
ing rod of 3 cm diameter with a non-slippery surface. The 
rod was placed at a height of 15 cm from the base. The 
rod, 30 cm in length, was divided into 5 equal sections by 
6 disks. Thus up to 5 mice were tested simultaneously on 
the apparatus, at a rod-rotating speed of 16 r.p.m. The 
integrity of motor coordination was assessed on the basis 
of the number of falls from the rod in 30 s according to 
Vaught et al. (1985). The performance time was measured 
before and 15, 30 and 45 min after subcutaneous adminis- 
tration of saline. The test was performed 8 and 12 days 
after pretreatment with vehicle or pertussis toxin. Naive 
animals were used as unpretreated controls. 
2.4. Drugs 
The following drugs were used: (+)  baclofen ([3-p- 
chlorophenyl GABA), physostigmine hemisulphate 
(Sigma), morphine hydrochloride (U.S.L. 10/D, Florence), 
clomipramine hydrochloride (anafranil, Ciba-Geigy), 
diphenhydramine hydrochloride (De Angeli) and pertussis 
toxin (RBI). 
All drugs were dissolved in isotonic (NaC1 0.9%) saline 
solution immediately before use, except for pertussis toxin 
which was dissolved in a water solution containing 0.01 M 
sodium phosphate buffer, pH 7.0, with 0.05 sodium chlo- 
ride. Drug concentrations were prepared in such a way that 
the necessary dose could be administered in a volume of 
10 ml kg- l  by subcutaneous ( .c.) injection. 
2.5. Intracerebroventricular injections 
Intracerebroventricular (i.c.v.) administration was per- 
formed under ether anaesthesia using isotonic saline as a 
solvent, according to the method described by Haley and 
McCormick (1957). Briefly, during anaesthesia, mice were 
grasped firmly by the loose skin behind the head. A 0.4 
mm external diameter hypodermic needle attached to a 10 
~1 syringe was inserted perpendicularly through the skull 
and no more than 2 mm into the brain of the mouse, where 
5 I~1 were then administered. The injection site was 1 mm 
to the fight or left from the midpoint on a line drawn 
through to the anterior base of the ears. Injections were 
performed into the right or left ventricle randomly. To 
ascertain that the drugs were administered exactly into the 
cerebral ventricle, some mice were injected with 5 Ixl of 
Indian ink diluted 1 : 10 and their brains were examined 
macroscopically after sectioning. 
2.6. Statistical analysis 
Results are given as the means ___ S.E.M.; an analysis of 
variance (ANOVA) was used to verify significance be- 
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tween two means. P values of less than 0.05 were consid- 
ered significant. Data were analysed with computer pro- 
gram (StatView for the Macintosh, 1992). 
3. Results 
3.1. Effect of pertussis toxin on mouse behaviour 
Table 1 shows the effects on mouse body weight pro- 
duced by the i.c.v, injection of pertussis toxin at the doses 
of 0.25 and 0.50 I~g per mouse in comparison with 
vehicle-treated and naive mice used as control animals. 
Both of the doses of pertussis toxin tested produced a loss 
of weight 2 days after iniection after which body weight 
slowly increased. In the pertussis toxin 0.50-treated group, 
a consistent number of deaths occurred (Table 1). When 
the dose of pertussis toxin was diminished to 0.25 ixg per 
mouse, the number of deaths was greatly reduced (Table 1) 
and the gross behaviour of pertussis toxin 0.25-treated 
mice was comparable to that of the vehicle-treated group. 
The body weight of naive and vehicle-treated mice pro- 
gressively increased and no deaths occurred (Table 1). 
The motor coordinatior, of mice pretreated with vehicle 
or pertussis toxin (0.25 and 0.50 ~g per mouse i.c.v.), and 
of naive mice was evaluated by using the rota-rod test 
(Fig. la,b). Rota-rod performance, tested as number of 
falls in 30 s, of animals pretreated 8 (Fig. la) and 12 days 
(Fig. lb) before the test with the doses of pertussis toxin 
investigated was not significantly impaired in comparison 
with that of naive and vehicle-treated mice as revealed by 
pretest values (Fig. la,b). Furthermore, the successive s.c. 
injections did not elicit any behavioural side effects since 
each group progressively ieduced the number of falls (Fig. 
la,b). No difference was observed between vehicle-treated 
and naive mice (Fig. la,b). 
3.2. Effect of pertussis toJ:in on the mouse pain threshold 
Treatment of animals with pertussis toxin (0.25 and 
0.50 Ixg per mouse i.c.v.) did not cause any modification 
of the pain threshold in comparison with controls 2 days 
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Fig. 1. Effect of pertussis toxin (PTX) in the mouse rota-rod test. Vehicle 
and pertussis toxin (0.25 and 0.50 ~zg per mouse) were injected i.c.v. 8 
days (panel A) or 12 days (panel B) before the test. Vertical lines give 
S.E.M.; the number of mice was 14 per group. 
after injection as revealed by the hot-plate test (Fig. 2). 
Mice receiving pertussis toxin at the dose of 0.50 ~g per 
mouse, but not at the dose of 0.25 Ixg per mouse, showed, 
7 days after injection, a statistically significant reduction of 
licking latency (14.0 + 0.5; n = 75) in comparison with 
the vehicle-treated group (15.3 ± 0.3; n = 130). A de- 
crease of the pain threshold was observed at both of the 
doses used 11 days after administration, showing a weak 
pertussis toxin-induced hyperalgesic effect (Fig. 2). 
Table 1 
Effects of pertussis toxin (PTX) after i.c.v, injection in mice on the body weight 
Treatment n Body weight (g) Deaths (%) 
i.c.v. Before treatment After treatment After treatment 
2 days 7 days 11 days 2 days 7 days 11 days 
Naive 34 2-';.8 ± 0.6 26.8 _+ 0.5 28.8 _+ 0.9 29.6 ± 0.9 0 0 0 
Vehicle 5 ~l 132 26.0 ± 0.2 26.7 ± 0.3 28.8 ___ 0.4 30.5 ± 0.5 0 0.7 0,7 
PTX 0.25 I.Lg 77 28.0 _+ 0.4 25.6 ± 0.5 b 26.9 ± 0.7 a 29.1 ± 0.8 0 6.5 23,4 
PTX 0.50 ~g 142 25.3 ± 0.2 21.5 ± 0.3 b 23.6 ± 0.5 b 24.3 ± 0.5 b 37.3 47.2 60,5 
Naive animals did not receive any treatment. The before treatment body weight was measured immediately before the i.c.v, injection, a p < 0.05, 
b p < 0.001 in comparison with the vehicle-treated mice. 
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Fig. 2. Effect of pertussis toxin (PTX) on pain threshold in the mouse 
hot-plate test 2, 7 and 11 days after a single pertussis toxin injection. 
Vehicle and pertussis toxin (0.25-0.50 p.g per mouse) were administered 
i.c.v.; vertical ines give S.E.M.; the number of mice was between 49 and 
130. * P < 0.05, * * P < 0.01 in comparison with vehicle-treated mice. 
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Fig. 3. Effect of pertussis toxin (PTX) pretreatment on morphine (7 mg 
kg I s.c.)-induced antinociception i the mouse hot-plate test. The test 
was performed 2 (panel A) and 7 (panel B) days after a single i.c.v. 
injection of vehicle or pertussis toxin (0.25 and 0.50 I~g per mouse). 
Vertical lines represent S.E.M.; the number of mice was between 11 and 
22. * P < 0.001, * * P < 0.001 in comparison with vehic le+morphine- 
treated mice. 
3.3. Effect of pertussis toxin on morphine-, diphenhy- 
dramine-, baclofen-, clomipramine- and physostigmine-in- 
duced antinociception 
The effect of pretreatment of mice with pertussis toxin 
(0.25 and 0.50 ~g per mouse i.c.v.) on morphine (Fig. 
3a,b)-, diphenhydramine (Fig. 4a,b)-, baclofen (Fig. 5a,b)-, 
clomipramine (Fig. 6a,b)- and physostigmine (Fig. 7a,b)- 
induced antinociception was evaluated in the mouse hot- 
plate test. 
Pretreatment with pertussis toxin (0.25 and 0.50 txg per 
mouse i.c.v.) 2 days before the test did not produce any 
significant effect on morphine (7 mg kg-l s.c.)-induced 
analgesia (Fig. 3a) whereas, 7 days after pertussis toxin 
administration, a complete prevention of morphine-induced 
antinociception i both pertussis toxin-treated groups was 
observed (Fig. 3b). 
Pertussis toxin (0.25 and 0.50 ~g per mouse i.c.v.), 
when injected 2 days prior to the test, was ineffective in 
preventing diphenhydramine (20 mg kg -1 s.c.)-induced 
antinociception (Fig. 4a). By contrast, when the toxin was 
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"'CY'- vehicle + d iphenhydramine  ----I-- PTX 0.50 + diphenhydramin¢ 
Fig. 4. Effect of pertussis toxin (PTX) pretreatment on diphenhydramine 
(20 mg kg-1 s.c.)-induced antinociception i the mouse hot-plate test. 
The test was performed 2 (panel A) and 7 (panel B) days after a single 
i.c,v, injection of vehicle or pcrtussis toxin (0.25 and 0.50 p,g per mouse). 
Vertical lines represent S.E.M.; the number of mice was between 11 and 
21, * P < 0.01, * * P < 0.001 on comparison with vehicle + 
dipenhydramine-treated mice, 
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injected 7 days before the test, it greatly reduced the 
antinociceptive effect of diphenhydramine (Fig. 4b). The 
pertussis toxin-induced prevention of the diphenhy- 
dramine-induced analgesia was not dose-dependent, being 
complete at both of the doses of pertussis toxin used (Fig. 
4a,b). 
Mice pretreated with pertussis toxin (0.25 and 0.50 Ixg 
per mouse i.c.v.) 2 and 7 days before the hot-plate test did 
not show any modified response to baclofen (4 mg kg-1 
s.c.) as compared with the vehicle-treated group (Fig. 
5a,b). Conversely, pertussis toxin pretreatment 11 days 
prior to the test was able to reduce baclofen-induced 
antinociception in a dose-dependent manner (Fig. 5c). 
The effect of i.c.v, injection of pertussis toxin (0.25 and 
0.50 Ixg per mouse) 2, 7 and 11 days before evaluation of 
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Fig. 5. Effect of  pertussis toxin (PTX) pretreatment on baclofen (4 mg 
kg- J  s.c.)-induced antinociception i the mouse hot-plate test. The test 
was performed 2 (panel A), 7 (panel B) and 11 (panel C) days after a 
single i.c.v, injection of  vehicle or pertussis toxin (0.25 and 0.50 i~g per 
mouse). Vertical lines represent S.E.M.; the number of mice was between 
12 and 22. * P < 0.05, * * P < 0.01, * * * P < 0.001 in comparison with 
vehicle + baclofen-treated mice. 
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Fig. 6. Effect of  pertussis toxin (PTX) pretreatment on clomipramine (25 
mg kg- I  s.c.)-induced antinociception i the mouse hot-plate test. The 
test was performed 2 (panel A), 7 (panel B) and 11 (panel C) days after a 
single i.c.v, injection of vehicle or pertussis toxin (0.25 and 0.50 p~g per 
mouse). Vertical lines represent S.E.M.; the number of  mice between 12 
and 22. * P<0.01 ,  ** P<0.001 in comparison with vehic le+ 
clomipramine-treated mice. 
the antinociception induced by clomipramine (25 mg kg-1 
s.c.) is reported in Fig. 6. Pertussis toxin pretreatment led 
to a loss of the antinociceptive effect of clomipramine. 
This reduction was obtained 11 days after pertussis toxin 
pretreatment and it was dose-dependent, 0.50 p,g being 
more effective than 0.25 p~g (Fig. 6c). No prevention of 
clomipramine-evoked antinociception was obtained on days 
2 and 7 (Fig. 6a,b). 
The effect of pertussis toxin (0.25 and 0.50 p~g per 
mouse) pretreatment on physostigmine-induced (0.1-0.2 
mg kg-1 s.c.) antinociception was evaluated 2, 7, 11 and 
14 days after pertussis toxin injection. Pertussis toxin, at 
both of the doses used, was never able to modify the 
antinociceptive effect of physostigmine (Fig. 7a,b). The 
licking latency values were recorded in correspondence 
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Fig. 7. Lack of effect of pertussis toxin (PTX) pretreatment on antinoci- 
ception induced by physostigmine at the doses of 0.1 mg kg- 1 s.c. (panel 
A) and 0.2 mg kg-1 s.c. (panel B) in the mouse hot-plate test. The test 
was performed 2, 7, 11 and 14 days after a single i.c.v, injection of 
vehicle or pertussis toxin (0.25 and 0.50 Ixg per mouse). The licking 
latency was measured 30 min after physostigmine administration. Vertical 
lines represent S.E.M.; the number of mice was between 6 and 22. 
^P < 0.05, ° P < 0.01, * P < 0.001 in comparison with vehicle+saline- 
treated mice. 
with the maximum effect of physostigmine that occurred 
30 min after administration. 
The i.c.v, injection of vehicle did not produce any 
modification of the sensitivity of animals to the analgesic 
treatments in comparison with naive mice (data not shown). 
4. Discussion 
The present study provides evidence for the involve- 
ment of pertussis toxin-sensitive G-proteins in central 
antinociception. Pretreatment with i.c.v, administration of
pertussis toxin produced an inhibition of morphine-, 
diphenhydramine-, baclofen- and clomipramine-induced 
analgesia, providing evidence for the important role of 
pertussis toxin-sensitive G-proteins as a transduction step 
in central antinociception. 
Pertussis toxin penetrates brain tissue slowly and in- 
completely. When the toxin is administered into the cere- 
bral ventricles, its distribution is limited to a narrow zone 
close to the ventricles (Van der Ploeg et al., 1991). This 
restricted istribution of pertussis toxin suggests, therefore, 
that the effects observed in behavioural studies after i.c.v. 
injection are attributable only to a central action. 
Pertussis toxin inactivates several G-proteins (Gi/o pro- 
teins) by ADP-ribosilation of a specific C-terminal cystein 
(Katada and Ui, 1982; Katada et al., 1984). The degree of 
ADP-ribosilation of Gi/o proteins was not evaluated by 
biochemical techniques. However, in confirmation of pre- 
vious studies in mice and rats (Parenti et al., 1986; Paro- 
laro et al., 1990; Chang et al., 1991; Chung et al., 1994), 
the morphine-induced analgesia was prevented by pertussis 
toxin pretreatment 7 days before the hot-plate test, making 
us certain that a sufficient level of inactivation of G~/o 
proteins was reached. Furthermore, the i.c.v, injection of 
antisense oligodeoxynucleotides against G~ and G~ proteins 
confirm the involvement of G i proteins in morphine-in- 
duced antinociception (Raffa et al., 1994) as previously 
postulated on the basis of the effects of PTX pretreatment. 
It is, therefore, supposed that PTX is a reliable tool to 
investigate the molecular mechanism of analgesic drugs. 
The antinociception induced by the histamine H 1 recep- 
tor antagonist diphenhydramine was prevented by pretreat- 
ing mice with pertussis toxin 7 days before the test. The 
administration of histamine H~ receptor antagonists pro- 
duces various inhibitory effects including analgesia 
(Rumore and Schlichting, 1985; Oluyomi and Hart, 1991), 
but their mechanism of action has not been elucidated. 
Histamine xerts its numerous actions through interaction 
with three pharmacologically distinct receptor subtypes, 
HI ,  H 2 and H3, which all belong to the superfamily of 
G-protein-coupled receptors (Arrang, 1994). Since it has 
been reported that histamine can modulate the release of 
several neurotransmitters (Hill, 1990), an involvement of 
neurotransmitters different from histamine, activating Gi/o 
proteins as a signal transduction mechanism, downstream 
from the initial receptor interaction cannot be excluded. 
Pertussis toxin, therefore, in preventing diphenhydramine- 
induced antinociception, could be working at histaminergic 
or non-histaminergic receptor-linked Gi/o proteins 
Injection of mice with pertussis toxin inhibited the 
antinociception i duced by the GABA B receptor agonist 
baclofen. GABA B receptors are located both spinally and 
supraspinally and they are coupled to pertussis toxin-sensi- 
tive G-proteins which inhibit adenylate cyclase activity 
(Wojcik and Neff, 1984; Hill, 1985) and modulate several 
ion channels (Houston et al., 1990; Gage, 1992). It was not 
unexpected, therefore, that pertussis toxin prevented ba- 
clofen-induced analgesia. Since it has been observed that 
baclofen-induced spinal antinociception is abolished by 
intrathecal pretreatment with pertussis toxin (Hoehn et al., 
1988), suggesting the involvement of a Gi/o protein in the 
baclofen spinal effect, it is now possible to extend to the 
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baclofen supraspinal antinc,ciceptive effect the presence of 
pertussis toxin-sensitive signal transduction mechanisms. 
Tricyclic antidepressant,; have long been known to pro- 
duce antinociception. The present results show that 
clomipramine-induced antinociception utilized a pertussis 
toxin-sensitive transductiorL mechanism. Clomipramine, as 
well as other tricyclic antidepressants, i  an inhibitor of 
serotonin reuptake. The increase of endogenous serotonin 
in the synaptic cleft produces directly (Galeotti et al., 
1995), or through the activation of endogenous opioid 
systems (Sacerdote t al., 1978), an increase in the pain 
threshold. Some serotonin (Lucas and Hen, 1995) and 
opioid (Loh and Smith, 1990) receptor subtypes have been 
reported to be coupled to pertussis toxin-sensitive G-pro- 
teins in the central nervous system. For this reason it is 
suggested that clomipramine, by activating the serotoniner- 
gic system, induces an analgesic effect underlying the 
activation of a signal transduction mechanism operated by 
Gi/o proteins. Even though we cannot exclude the involve- 
ment of the opioid system in clomipramine-induced 
antinociception, it seems to be unlikely since clomipramine 
was sensitive to pertussis :Loxin pretreatment only on day 
11 while morphine was sensitive on day 7. 
The analgesic effect of diphenhydramine, as well as that 
of morphine, was inhibited by pretreating animals with 
pertussis toxin 7 days before the test, whereas baclofen- 
and clomipramine-induced antinociception was prevented 
by pertussis toxin 11 days after the injection of the toxin. 
To ensure a good ADP-ribosilation of the pertussis toxin- 
sensitive G-proteins, a lalency of at least 48-72 h is 
necessary (Van der Ploeg et al., 1991). The 11-day latency 
necessary to block baclofen- and clomipramine-induced 
analgesia, compared with the 7-day latency required for 
inhibiting morphine- and diphenhydramine-induced 
antinociception, might be due to the difficulty of pertussis 
toxin of reaching the zone where GABA B and serotonin 
receptors are located in the highest concentration. 
Physostigmine is a cholinesterase inhibitor that en- 
hances the level of synapti,: acetylcholine by inhibiting its 
degradation. Some muscarinic receptor subtypes have been 
reported to be coupled to pertussis toxin-sensitive G-pro- 
teins (the M 2 and M 4 subtypes) modulating adenylate 
cyclase and several ion channels, whereas others, such as 
M~, M 3 and M 5, are linked to G-proteins that activate 
phospholipase C (Caulfield, 1993). The agonist regulation 
of phospholipase C appears to involve at least two separate 
mechanisms: the activation of a pertussis toxin-sensitive 
G-protein or, more commonly, the activation of pertussis 
toxin-insensitive G-proteins (Park et al., 1993). Even 
though the most widespread muscarinic receptor subtypes 
in the central nervous ystem are MI, M 2 and M4, pertus- 
sis toxin pretreatment did not affect physostigmine 
antinociception. The lack of effect of pertussis toxin could 
be due to the fact that the receptor subtype mainly in- 
volved in physostigmine-induced antinociception is the M~ 
subtype. In support of this hypothesis, it has been reported 
that muscarinic M~ receptor agonists produce antinocicep- 
tion in mice and rats that is prevented by muscarinic M 1 
receptor selective antagonists (Bartolini et al., 1992). Fur- 
thermore, it has been observed that the human M l recep- 
tor, expressed in Chinese hamster oocytes (CHO), selec- 
tively activates Gq and Gl~ proteins (Mullaney et al., 
1993). It seems, therefore, reasonable to suppose that 
physostigmine, by enhancing acetylcholine l vels, induces 
antinociception through a molecular mechanism that does 
not involve Gi/o proteins. 
The doses of the investigated analgesic ompounds used 
were chosen on the basis of the rota-rod test (data not 
shown). Higher doses were not used since they impaired 
the rota-rod performance and could lead to a misinterpreta- 
tion of the results obtained. As pertussis toxin prevented 
the antinociception i duced by all the compounds used, 
with the exception of physostigmine, lower doses were not 
investigated. The effect of physostigmine, at both of the 
doses used (0.1-0.2 mg kg-l s.c.), was never prevented 
by pertussis toxin pretreatment. Doses of physostigmine 
lower than 0.1 mg kg 1 s.c. could not be investigated 
since they were not endowed with analgesic properties. 
Pertussis toxin prevents the activation, by receptor stim- 
ulation, of Gi/o proteins which are involved in the actions 
of several inhibitory neurotransmitters. For this reason 
i.c.v, injection of the toxin has been reported to produce 
widespread side effects which can make interpretation of
results from behavioural studies difficult (Bodnar et al., 
1990). It has been previously reported that doses of pertus- 
sis toxin of 0.25 and 0.50 p,g per mouse i.c.v. (Damaj et 
al., 1994; Suzuki et al., 1991) do not produce any signifi- 
cant reduction in mouse body weight. By contrast, in our 
conditions mice treated with a dose of pertussis toxin of 
0.50 and 0.25 p,g per mouse i.c.v, weighed approximately 
20% and 10%, respectively, less than controls. Even though 
a loss of body weight occurred, the motor coordination of 
mice pretreated with both of the doses of pertussis toxin 
used was not impaired, making the results obtained in the 
hot-plate test reliable. 
Pertussis toxin, starting from 7 days after administra- 
tion, produced a statistically significant reduction of the 
pain threshold, showing a weak hyperalgesic effect as 
previously reported (Ohnishi et al., 1990). However, the 
prevention of morphine, diphenhydramine-, baclofen- and 
clomipramine-induced antinociception cannot be at- 
tributable to pertussis toxin-induced hyperalgesia. The re- 
duction of the pain threshold produced by pertussis toxin 
was of the same intensity at both of the doses used, 
whereas the toxin inhibited the effects of the above-men- 
tioned analgesic drugs dose dependently. Furthermore, the 
effect of pertussis toxin on baclofen- and clomipramine-in- 
duced antinociception was not detectable 7 days after the 
administration of the toxin while the pertussis toxin-in- 
duced reduction of the pain threshold was already present. 
Finally, pertussis toxin, even though it is endowed with 
hyperalgesic properties, was never able to modify 
132 N. Galeotti et al. / European Journal of Pharmacology 308 (1996) 125-133 
physostigmine-induced antinociception, supporting the hy- 
pothesis that the reduction of the pain threshold produced 
by the toxin is not responsible for the neutralization f the 
antinociception induced by the investigated compounds. 
In conclusion, the present data demonstrated that per- 
tussis toxin-sensitive G-proteins represent an essential step 
in the transduction mechanism underlying central antinoci- 
ception. An increase in pain threshold can be induced by 
activating different neurotransmitter systems, such as opi- 
old, GABAergic, serotoninergic and histaminergic, that, 
however, produce the activation of Gi/o proteins as a 
common molecular event. 
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